

Addressing the Growing Threat of Securities Class Actions in the Life Sciences Sector

December 6, 2016 | Client Update

Life sciences companies are frequent targets of securities litigation. Often, when a company discloses bad news about a developing device or drug, the company's stock price drops and plaintiffs' lawyers pounce. They claim that the company's prior statements about the drug or device were too rosy. The attached memorandum addresses that all-too-typical fact pattern and describes the body of case law that has developed for assessing liability when a company has offered opinions about a new potential product.

If you have any questions regarding the matters covered in this publication, please reach out to any of the lawyers listed below or your usual Davis Polk contact.

Bruce K. Dallas

+1 650 752 2022
bruce.dallas@davispolk.com

Alan F. Denenberg

+1 650 752 2004
alan.denenberg@davispolk.com

Michael S. Flynn

+1 212 450 4766
michael.flynn@davispolk.com

Edmund Polubinski

+1 212 450 4695
edmund.polubinski@davispolk.com

Lawrence Portnoy

+1 212 450 4874
lawrence.portnoy@davispolk.com

Neal Potischman

+1 650 752 2021
neal.potischman@davispolk.com

James P. Rouhandeh

+1 212 450 4835
rouhandeh@davispolk.com

Richard D. Truesdell, Jr.

+1 212 450 4674
richard.truesdell@davispolk.com

This communication, which we believe may be of interest to our clients and friends of the firm, is for general information only. It is not a full analysis of the matters presented and should not be relied upon as legal advice. This may be considered attorney advertising in some jurisdictions. Please refer to the firm's privacy notice for further details.

Related materials

[Read the full update](#)